

HUMAN SERVICES

Iowa Department of Human Services

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Request for Prior Authorization CGRP Inhibitors

(PLEASE PRINT – ACCURACY IS IMPORTANT IA Medicaid Member ID # Patient name DOB Patient address Provider NPI Prescriber name Phone Prescriber address Fax Pharmacy name Address Phone Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. Pharmacy NPI Pharmacy fax NDC

Prior authorization is required for CGRP Inhibitors. Payment will be considered for a FDA approved or compendia indicated diagnosis under the following conditions:

- 1. Patient has one of the following diagnoses:
 - a. Chronic Migraine, defined as:
 - i. ≥ 15 headache days per month for a minimum of 3 months; and
 - ii. ≥ 8 migraine headache days per month for a minimum of 3 months; or
 - b. Episodic Migraine, defined as:
 - i. 4 to 14 migraine days per month for a minimum of 3 months; or
 - c. Episodic Cluster Headache, defined as:
 - i. Occurring with a frequency between one attack every other day and 8 attacks per day; and
 - ii. With at least 2 cluster periods lasting 7 days to one year (when untreated) and separated by pain-free remission periods of ≥ 3 months; and
 - iii. Patient does not have chronic cluster headache (attacks occurring without a remission period, or with remissions lasting < 3 months, for at least 1 year); and
- 2. Patient meets the FDA approved age for submitted diagnosis; and
- 3. Patient has been evaluated for and does not have medication overuse headache; and
- 4. For Episodic and Chronic Migraine, patient has documentation of three trials and therapy failures, of at least three months per agent, at a maximally tolerated dose with a minimum of two different migraine prophylaxis drug classes (i.e., anticonvulsants [divalproex, valproate, topiramate], beta blockers [atenolol, metoprolol, nadolol, propranolol, timolol], antidepressants [amitriptyline, venlafaxine]; or
- 5. For Episodic Cluster Headache, patient has documentation of:
 - a. A previous trial and therapy failure at an adequate dose with glucocorticoids (prednisone 30mg per day or dexamethasone 8mg BID) started promptly at the start of a cluster period. Failure is defined as the need to use acute/abortive medications (oxygen, triptans, ergotamine, lidocaine) at least once daily for at least two days per week after the first full week of adequately dosed steroid therapy; and
 - b. A previous trial and therapy failure at an adequate dose of verapamil for at least 3 weeks (total daily dose of 480mg to 960mg). Failure is defined as the need to use acute/abortive medications (oxygen, triptans, ergotamines, lidocaine) at least once daily for at least two days per week after three weeks of adequately dosed verapamil therapy.
- 6. The requested dose does not exceed the maximum FDA labeled dose for the submitted diagnosis; and
- 7. Lost, stolen, or destroyed medication replacement requests will not be authorized.

470-5554 (Rev 1/20) Page 1 of 3

Request for Prior Authorization CGRP Inhibitors

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Initial requests will be approved for three months. Additional prior authorizations will be considered upon documentation of clinical response to therapy (i.e., reduced migraine frequency, reduced migraine headache days, reduced weekly cluster headache attack frequency).

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Non-Prefer Aimovig		☐ Emgality		
	Strength	Dosage Instructions	Quantity	Days Supply
1. F	c Migraine (mus Patient has ≥ 15 Number of heada	st document each criterion bel headache days per month for a ache days each month: Month 2:	minimum of 3 mont	
2. F	Patient has ≥ 8 n Number of migra	nigraine headache days per mor ine headache days each month: Month 2:	nth for a minimum of	f 3 months
 1. F	Number of migra	14 migraine headache days per ine headache days each month: Month 2:		
		nine treatment failures:		Trial Dates:
[:] ailure reas	son:			
				Trial Dates:
				Table 1
				_ I rial Dates:
				_
Episodi	ic Cluster Head	ache (must document each cr	iterion below):	
		equency between one attack eve	•	

470-5554 (Rev 1/20) Page 2 of 3

pain-free remission periods of ≥ 3 months:

2. Patient has at least 2 cluster periods lasting 7 days to one year (when untreated) and separated by

Iowa Department of Human Services

Request for Prior Authorization CGRP Inhibitors

(PLEASE PRINT - ACCURACY IS IMPORTANT)

		# of cluster periods:	_Length of cluste	r periods:					
		Does patient have pain-free remission periods? Yes No							
		If yes, length of pain-free remission periods:							
	3.	Does patient have chronic cluster headach	e? 🗌 Yes 🔲 1	No					
Epis	odic	Cluster Headache treatment failures:							
Glud	cocor	ticoid Trial: Name/Dose:		Trial Dates:					
Failure reason:									
Verapamil Trial: Name/Dose: Trial Dates:									
Failure reason:									
Has patient been evaluated and medication overuse headache ruled out? Yes No Renewal Requests: Document clinical response to therapy:									
	For	or chronic or episodic migraine: number of headache/migraine days per month since start of therapy:							
	For	r episodic cluster headache: number of cluster periods since start of therapy:							
Possible drug interactions/conflicting drug therapies:									
Atta	ch la	b results and other documentation as ned	cessarv.						
Prescriber signature (Must match prescriber listed above.)				Date of submission					

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

470-5554 (Rev 1/20) Page 3 of 3